Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.81 |
| ▸ | CCKBR | P32239 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ALB | P02768 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8726311 | 0.90 | CHRM1 (1.00) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL21272221 | 0.90 | CHRM1 (1.00) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL21272219 | 0.90 | CHRM1 (1.00) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL31366559 | 0.87 | CHRM1 (0.83) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL25413413 | 0.87 | CHRM1 (0.83) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL25413405 | 0.87 | CHRM1 (0.83) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL25413417 | 0.87 | CHRM1 (0.83) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL25413103 | 0.85 | CHRM1 (0.80) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL25413102 | 0.85 | CHRM1 (0.80) | CHRM1CCKBRMEN1LMNAALB | |
| SCHEMBL25410981 | 0.85 | CHRM1 (0.79) | CHRM1CCKBRMEN1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| EP-1636197-A1 | NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES | Aston University (GB) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004106310-A1 | NOVEL 3-SUBSTITUTED-1,4-BENZODIAZEPINES | ASTON UNIVERSITY (GB) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | CCKBR, CCKAR, GABRB1 | CHRM1 340/4885CCKBR 1/4885MEN1 2746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.